Pregled bibliografske jedinice broj: 1214341
RPE65 c.353G>A, p.(Arg118Lys): A Novel Point Mutation Associated with Retinitis Pigmentosa and Macular Atrophy
RPE65 c.353G>A, p.(Arg118Lys): A Novel Point Mutation Associated with Retinitis Pigmentosa and Macular Atrophy // International Journal of Molecular Sciences, 23 (2022), 18; 10513, 9 doi:10.3390/ijms231810513 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1214341 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
RPE65 c.353G>A, p.(Arg118Lys): A Novel Point Mutation Associated
with Retinitis Pigmentosa and Macular Atrophy
Autori
Bjeloš, Mirjana ; Bušić, Mladen ; Ćurić, Ana ; Šarić, Borna ; Bosnar, Damir ; Marković, Leon ; Kuzmanović Elabjer, Biljana ; Rak, Benedict
Izvornik
International Journal of Molecular Sciences (1422-0067) 23
(2022), 18;
10513, 9
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
retinal dystrophies ; night blindness ; retinitis pigmentosa ; genetic therapy
Sažetak
Precise genetic diagnosis in RPE65-mediated retinitis pigmentosa (RP) is necessary to establish eligibility for genetic treatment with voretigene neparvovec: a recombinant adeno-associated viral vector providing a functional RPE65 gene. This case report aims to report a novel RP-related point mutation RPE65 c.353G>A, p.(Arg118Lys), a variant of uncertain significance associated with a severe clinical presentation and the striking phenotypic feature of complete macular atrophy. We report the case of a 40-year-old male with inherited retinal dystrophy, all features typical for the RPE65-associated RP, and marked macular atrophy. Genetic testing identified that the patient was a compound heterozygote in trans form with two heterozygous variants: RPE65 c.499G>T, p.(Asp167Tyr) and RPE65 c.353G>A, p.(Arg118Lys). Furthermore, short-wavelength and near- infrared autofluorescence patterns exhibited deficiencies specific to mutations in the visual cycle genes. To the best of our knowledge, RPE65 c.353G>A, p.(Arg118Lys) is the first described point mutation on this locus, among all other reported insertional mutations, currently classified as likely benign and of uncertain significance. We concluded that this variant contributed to the pathological phenotype, demonstrating its significance clearly to be reclassified as likely pathogenic. This being the case, patients with this specific variant in homozygous or compound heterozygous form would be likely candidates for genetic treatment with voretigene neparvovec.
Izvorni jezik
Engleski
POVEZANOST RADA
Profili:
Biljana Kuzmanović Elabjer
(autor)
Borna Šarić
(autor)
Mirjana Bjeloš
(autor)
Damir Bosnar
(autor)
Ana Križanović
(autor)
Mladen Bušić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE